What is the difference between Cagrilintide and CagriSema?

Cagrilintide is the amylin analogue on its own. CagriSema is the fixed combination of Cagrilintide and the GLP-1 agent Semaglutide. The meta-analysis reports both separately.

What was the most important result?

The paper's core message: CagriSema was more effective for weight loss than Semaglutide alone, with a comparable safety profile. The notable secondary finding: Cagrilintide as monotherapy achieved weight loss comparable to Semaglutide.

How serious is the RR 1.83 safety signal?

It concerns serious adverse events under Cagrilintide monotherapy. The confidence interval runs from 1.03 to 3.24, so the lower bound is just above 1. With only three studies this is a signal worth watching, not a final verdict. The authors rate the CagriSema combination as comparable to Semaglutide in terms of safety.

Is Cagrilintide approved?

No. Cagrilintide is not approved as a medicine and remains a research peptide. This article reports solely on study data.

Cagrilintide Alone Versus Semaglutide: What the New 2026 Meta-Analysis Actually Shows

Important notice: This article is intended solely for scientific information and research purposes. Cagrilintide is a research peptide, not intended for human consumption and not approved as a medicine. No therapeutic recommendations or dosing instructions are given.

TL;DR: What the meta-analysis summarizes

Source: Systematic review plus meta-analysis plus meta-regression, published 2026 in Diabetes, Obesity and Metabolism. Three randomized trials, 3,545 participants in total. Main finding of the paper: The combination CagriSema (Cagrilintide plus Semaglutide) was more effective for weight loss than Semaglutide alone, with a comparable safety profile. The overlooked detail: Cagrilintide as monotherapy achieved weight loss comparable to Semaglutide, but showed a higher signal for serious adverse events (relative risk 1.83). Context: A signal, not a verdict. Three studies are a narrow basis, and the confidence interval is wide.

Cagrilintidemetabolic

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

What this is about

After 2026, amylin is the hottest side field in weight-loss research. Cagrilintide is a long-acting amylin analogue that makes headlines above all in combination with Semaglutide: this combination is called CagriSema. The new meta-analysis pools the randomized data available so far and places three comparisons side by side: CagriSema versus Semaglutide, Cagrilintide monotherapy versus Semaglutide, and the respective safety profiles.

The paper's headline is the one about CagriSema. For research into Cagrilintide itself, however, the monotherapy comparison is the more interesting part, and that is exactly the part that usually gets lost in the press coverage.

Study basis

Three randomized controlled trials, 3,545 participants in total, observation periods of roughly 26 to 32 weeks. Methodology: systematic review, meta-analysis and meta-regression. Weight loss, gastrointestinal tolerability and serious adverse events were compared. The effect measures are relative risks with 95 percent confidence intervals.

The three findings in plain terms

1. CagriSema beats Semaglutide on weight. The combination led to roughly 7.6 kg more weight loss in absolute terms than Semaglutide alone. That is the main finding and the reason CagriSema, as a dual mechanism, gets so much attention.

2. Cagrilintide alone is on par with Semaglutide on weight. As a monotherapy, Cagrilintide achieved weight loss comparable to Semaglutide. That is remarkable for an amylin analogue on its own, because Semaglutide is the established benchmark.

3. The monotherapy safety signal is more nuanced. For Cagrilintide as a monotherapy, the analysis found a higher relative risk for serious adverse events: RR 1.83 with a 95 percent confidence interval of 1.03 to 3.24.

How to read the safety signal

A relative risk of 1.83 sounds substantial, but the confidence interval runs from 1.03 to 3.24. The lower bound sits just above 1, so the signal is only just statistically meaningful and carries considerable uncertainty. Three studies are also a narrow data basis. This is a pointer that deserves further observation, not a final safety verdict. Important: the authors themselves rate the safety of the CagriSema combination as comparable to Semaglutide. The monotherapy signal is a secondary finding, not the paper's core message.

Why the distinction matters

It is tempting to turn "higher adverse-event signal with Cagrilintide monotherapy" into a headline against amylin analogues. That would be an overinterpretation. What the data actually suggest:

Cagrilintide on its own produces a meaningful weight effect that can keep pace with the gold standard.
In combination with Semaglutide, the effects add up to a clear advantage on weight.
The monotherapy safety signal is real enough to mention, but too uncertain to derive a recommendation from it.

For scientific context this means: amylin agonism is a distinct, promising mechanism, and the most exciting research question is how it can be combined with incretin agents.

Mechanism, briefly

Amylin is released together with insulin and acts on satiety and gastric emptying. Cagrilintide is a long-acting amylin analogue. While GLP-1 agents such as Semaglutide act on a different receptor system, the amylin pathway complements the satiety signals. That explains why combining both pathways acts additively.

Cagrilintide in the comparative field

Cagrilintide does not stand alone. Anyone who lays the metabolic peptides side by side sees a whole spectrum of mechanisms: pure amylin (Cagrilintide), GLP-1 (Semaglutide), dual GLP-1 plus GIP (Tirzepatide) and triple GLP-1 plus GIP plus glucagon (Retatrutide). The choice of research model depends on which question is to be answered.

Cagrilintidemetabolic

Long-acting amylin analog studied for once-weekly satiety and appetite control. Phase 3 REDEFINE trials complete, NDA filed with FDA December 2025. A mechanism distinct from GLP-1 agonists.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Quality with unapproved investigational peptides

Identity and purity count

Cagrilintide is not approved as a medicine. With an investigational peptide that lacks officially controlled production, independent batch analysis is the real mark of quality. Our batches are tested at Janoshik for identity and purity, the certificate is viewable per batch and can be cross-checked via the verify function.

FAQ

Sources

Ahmed M. et al. "Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression." Diabetes, Obesity and Metabolism, 2026. PubMed-ID 41834765. https://pubmed.ncbi.nlm.nih.gov/41834765/
Full text, Diabetes, Obesity and Metabolism, doi:10.1111/dom.70667. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70667
CagriSema primary trials, New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2502081

Research disclaimer: All content is intended solely for scientific information. Cagrilintide is not intended for human consumption and not approved as a medicine. The figures cited come from a meta-analysis and do not replace medical advice.